A double-blind, randomized, placebo-controlled trial of paroxetine controlled-release in irritable bowel syndrome

Psychosomatics

Volumn 50, Issue 1, 2009, Pages 78-86

  Masand, Prakash S ^a   Pae, Chi Un ^b   Krulewicz, Stan ^b   Peindl, Kathleen ^b   Mannelli, Paolo ^b   Varia, Indu M ^b   Patkar, Ashwin A ^b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; ANXIETY; APPETITE; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COMPOSITE PAIN SCORE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; GYNECOLOGIC DISEASE; HEADACHE; HUMAN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NIGHTMARE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; SWEATING; TREATMENT OUTCOME; VIVID DREAM; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ANALYSIS OF VARIANCE; CHI-SQUARE DISTRIBUTION; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; PAIN MEASUREMENT; PAROXETINE; PLACEBOS; TREATMENT OUTCOME;

EID: 61849161180     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.50.1.78     Document Type: Article

References (48)

1. Manning AP, Thompson WG, Heaton KW, et al: Toward positive diagnosis of the irritable bowel. BMJ 1978; 2:653-654
2. Garakani A, Win T, Virk S, et al: Comorbidity of irritable bowel syndrome in psychiatric patients: a review. Am J Ther 2003; 10:61-67
3. Mertz HR: Irritable bowel syndrome. N Engl J Med 2003; 349:2136-2146
4. Drossman DA, Li Z, Andruzzi E, et al: U.S. Householder Survey of Functional Gastrointestinal Disorders: Prevalence, Sociodemography, and Health Impact. Dig Dis Sci 1993; 38:1569-1580
5. Maxion-Bergemann S, Thielecke F, Abel F, et al: Cost of irritable bowel syndrome in the U.K. and U.S. Pharmacoeconomics 2006; 24:21-37
6. Gilkin RJ Jr: The spectrum of irritable bowel syndrome: a clinical review. Clin Ther 2005; 27:1696-1709
7. Norton N: Functional Bowel Disorders Survey. Participate 1997; 6:1-3
8. Burke P, Elliott M, Fleissner R: Irritable bowel syndrome and recurrent abdominal pain: a comparative review. Psychosomatics 1999; 40:277-285
9. Drossman DA, McKee DC, Sandler RS, et al: Psychosocial factors in the irritable bowel syndrome: a multivariate study of patients and nonpatients with irritable bowel syndrome. Gastroenterology 1988; 95:701-708
10. Kaplan DS, Masand PS, Gupta S: The relationship of irritable bowel syndrome (IBS) and panic disorder. Ann Clin Psychiatry 1996; 8:81-88
11. Masand PS, Kaplan DS, Gupta S, et al: Major depression and irritable bowel syndrome: is there a relationship? J Clin Psychiatry 1995; 56:363-367
12. Masand PS, Kaplan DS, Gupta S, et al: Irritable bowel syndrome and dysthymia: is there a relationship? Psychosomatics 1997; 38:63-69
13. Masand PS, Gupta S, Schwartz TL, et al: Paroxetine in patients with irritable bowel syndrome: a pilot, open-label study. Prim Care Companion J Clin Psychiatry 2002; 4:12-16
14. Masand PS, Keuthen NJ, Gupta S, et al: Prevalence of irritable bowel syndrome in obsessive-compulsive disorder. CNS Spectr 2006; 11:21-25
15. Tollefson GD, Luxenberg M, Valentine R, et al: An open-label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder. J Clin Psychiatry 1991; 52:502-508
16. Masand PS, Gupta S, Schwartz TL, et al: Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome? Psychosomatics 2002; 43:451-455
17. Drossman DA, Camilleri M, Mayer EA, et al: AGA Technical Review on Irritable Bowel Syndrome. Gastroenterology 2002; 123:2108-2131
18. Dinan TG, O'Keane V, O'Boyle C, et al: A comparison of the mental status, personality profiles, and life events of patients with irritable bowel syndrome and peptic ulcer disease. Acta Psychiatr Scand 1991; 84:26-28
19. Dancey CP, Taghavi M, Fox RJ: The relationship between daily stress and symptoms of irritable bowel: a time-series approach. J Psychosom Res 1998; 44:537-545
20. Lydiard RB, Falsetti SA: Experience with anxiety and depression treatment studies: implications for designing irritable bowel syndrome clinical trials. Am J Med 1999;107:65S-73S
21. Read NW, Gwee KA: The importance of 5-hydroxytryptamine receptors in the gut. Pharmacol Ther 1994; 62:159-173
22. Richardson BP, Engel G: The pharmacology and function of 5-HT3 receptors. Trends Neurosci 1986; 9:424-429
23. Gerhson MD: Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13(suppl 2):15-30
24. Akehurst R, Kaltenthaler E: Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48:272-282
25. Jailwala J, Imperiale TF, Kroenke K: Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med 2000; 133:136-147
26. Jackson JL, O'Malley PG, Tomkins G, et al: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108:65-72
27. O'Malley PG, Jackson JL, Santoro J, et al: Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48:980-990
28. Chial HJ, Camilleri M, Burton D, et al: Selective effects of serotonergic psychoactive agents on gastrointestinal functions in health. Am J Physiol Gastrointest Liver Physiol 2003; 284:G130-137
29. Kato O, Misawa H: Treatment of diarrhea-predominant irritable bowel syndrome with paroxetine. Prim Care Companion J Clin Psychiatry 2005; 7:202
30. Masand PS, Gupta S, Schwartz TL, et al: Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry 2005; 7:162-166
31. Tabas G, Beaves M, Wang J, et al: Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol 2004; 99:914-920
32. Creed F, Guthrie E, Ratcliffe J, et al: Does psychological treatment help only those patients with severe irritable bowel syndrome who also have a concurrent psychiatric disorder? Aust N Z J Psychiatry 2005; 39:807-815
33. Tack J, Broekaert D, Fischler B, et al: A controlled cross-over study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006 (in press)
34. Kuiken SD, Tytgat GN, Boeckxstaens GE: The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1:219-228
35. Vahedi H, Merat S, Rashidioon A, et al: The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind, randomized-controlled study. Aliment Pharmacol Ther 2005; 22:381-385
36. Patkar AA, Peindl K, Krulewicz S, et al: History of depressive and anxiety disorders as predictors of response in fibromyalgia. 158th Annual Meeting of American Psychiatric Association, Atlanta, GA, May 21-26, 2005
37. Talley NJ: Antidepressants in IBS: are we deluding ourselves? Am J Gastroenterol 2004; 99:921-923
38. Sheehan DV, Eaddy M, Sarnes M, et al: Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine. J Clin Psychopharmacol 2004; 24:544-548
39. Keene MS, Eaddy MT, Nelson WW, et al: Adherence to paroxetine-CR compared with paroxetine-IR in a Medicare-eligible population with anxiety disorders. Am J Manag Care 2005; 11(suppl 12):S362-S369
40. Eaddy M, Bramley T, Regan T: Time-to-antidepressant discontinuation: a comparison of controlled-release paroxetine and immediate-release selective serotonin-reuptake inhibitors. Manag Care Interface 2003; 16:22-27
41. Thompson WG, Longstreth G, Drossman DA, et al: Functional bowel disorders and functional abdominal pain, in The Functional Gastrointestinal Disorders, 2nd Edition. Edited by Drossman DA, Corazziari E, Talley NJ, et al. McLean, VA, Degnon Associates, 2000, pp 351-432
42. Sheehan DV, Lecrubier Y, Sheehan KH, et al: The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(suppl 20):22-33
43. Kobak KA, Taylor LH, Dottl SL, et al: A computer-administered telephone interview to identify mental disorders. JAMA 1997; 278:905-910
44. Guy W (ed.): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Rockville, MD, U.S. Dept. of Health, Education, and Welfare, 1976, pp 217-222
45. Levine J, Schooler NR: SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 1986; 22:343-381
46. Drossman DA, Toner BB, Whitehead WE, et al: Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate-to-severe functional bowel disorders. Gastroenterology 2003; 125:19-31
47. Gorard DA, Libby GW, Farthing MJ: Influence of antidepressants on whole-gut and orocaecal transit times in health and irritable bowel syndrome. Aliment Pharmacol Ther 1994; 8:159-166
48. Minocha A, Chad W, Do W, et al: Racial differences in epidemiology of irritable bowel syndrome alone, un-investigated dyspepsia alone, and "overlap syndrome" among African Americans compared to Caucasians: a population-based study. Dig Dis Sci 2006; 51:218-226